{"title":"多克隆抗淋巴细胞制剂在心脏移植预防中的应用。","authors":"J A Carey, W H Frist","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Polyclonal antilymphocytic preparations, heterologous antibodies to human lymphoid cells, have been administered to heart transplant recipients prophylactically in the immediate perioperative period to avert rejection. The current status of the three classes of polyclonal preparations (antilymphoblast globulins, antithymocyte globulins, and antithymocyte sera) and their clinical role for prophylaxis in heart transplantation are summarized.</p>","PeriodicalId":77638,"journal":{"name":"The Journal of heart transplantation","volume":"9 3 Pt 2","pages":"297-300"},"PeriodicalIF":0.0000,"publicationDate":"1990-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Use of polyclonal antilymphocytic preparations for prophylaxis in heart transplantation.\",\"authors\":\"J A Carey, W H Frist\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Polyclonal antilymphocytic preparations, heterologous antibodies to human lymphoid cells, have been administered to heart transplant recipients prophylactically in the immediate perioperative period to avert rejection. The current status of the three classes of polyclonal preparations (antilymphoblast globulins, antithymocyte globulins, and antithymocyte sera) and their clinical role for prophylaxis in heart transplantation are summarized.</p>\",\"PeriodicalId\":77638,\"journal\":{\"name\":\"The Journal of heart transplantation\",\"volume\":\"9 3 Pt 2\",\"pages\":\"297-300\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1990-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of heart transplantation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of heart transplantation","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Use of polyclonal antilymphocytic preparations for prophylaxis in heart transplantation.
Polyclonal antilymphocytic preparations, heterologous antibodies to human lymphoid cells, have been administered to heart transplant recipients prophylactically in the immediate perioperative period to avert rejection. The current status of the three classes of polyclonal preparations (antilymphoblast globulins, antithymocyte globulins, and antithymocyte sera) and their clinical role for prophylaxis in heart transplantation are summarized.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
